INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 88 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2013. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2015 | $7,602,000 | -20.6% | 45,835 | +15.5% | 0.02% | -8.0% |
Q2 2015 | $9,576,000 | -53.1% | 39,671 | -45.2% | 0.02% | -51.9% |
Q1 2015 | $20,426,000 | -52.2% | 72,428 | -59.9% | 0.05% | -51.4% |
Q3 2014 | $42,720,000 | -55.9% | 180,491 | -55.9% | 0.11% | -2.7% |
Q2 2014 | $96,846,000 | +1916.8% | 409,270 | +481.9% | 0.11% | +900.0% |
Q4 2013 | $4,802,000 | -53.8% | 70,334 | -53.3% | 0.01% | -54.2% |
Q3 2013 | $10,389,000 | +52.5% | 150,501 | -0.9% | 0.02% | +50.0% |
Q2 2013 | $6,812,000 | – | 151,913 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Carmignac Gestion | 2,028,192 | $229,389,000 | 1.76% |
Orbimed Advisors | 1,037,000 | $117,285,000 | 1.33% |
BB BIOTECH AG | 255,719 | $28,922,000 | 0.95% |
ALTRINSIC GLOBAL ADVISORS LLC | 193,369 | $21,870,000 | 0.74% |
FALCON POINT CAPITAL, LLC | 44,573 | $5,041,000 | 0.67% |
Rhenman & Partners Asset Management AB | 30,000 | $3,393,000 | 0.54% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 11,155 | $1,262,000 | 0.48% |
NATIONAL PLANNING CORP | 52,400 | $5,888,000 | 0.44% |
HIGHFIELDS CAPITAL MANAGEMENT LP | 364,232 | $41,195,000 | 0.38% |
SPHERA FUNDS MANAGEMENT LTD. | 15,000 | $1,697,000 | 0.33% |